Perfusion Cell Culture Patents: Top Companies & Trends 2026
Perfusion Cell Culture Process Patents: Who Files, What They Claim
Five filers cover 81.4% of all 118 records in scope, leaving a genuine long tail rather than a broad competitive field. Annual filings rose to a peak of 24 records in 2018 before easing off; 2026 is a partial year and should not be read as a decline. With fewer than four complete years remaining once publication lag is accounted for, no growth rate is stated here.
- 1BOEHRINGER INGELHEIM INT GMBH35
- 2AMGEN INC21
- 3ER SQUIBB & SONS LLC20
- 4BAYER HEALTHCARE LLC13
- 5MERCK PATENT GMBH7
See the full perfusion cell culture processes analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most patents on perfusion cell culture processes?
One assignee leads this dataset with 35 of the 118 records in scope, well ahead of the fifth-ranked filer at 7 records. The top five assignees together hold 81.4% of all records, and the top ten reach 94.1%, so the field is concentrated among a small group of large biologics manufacturers and process-engineering suppliers rather than spread evenly. Anyone assessing freedom to operate should start with that leading group before looking at the long tail of smaller filers.
What technology areas do perfusion cell culture patents cover?
Claims cluster heavily in genetic engineering and microorganism handling (C12N, 50.0% of the 118 records) and fermentation or enzymatic synthesis (C12P, 43.2%), with bioreactor hardware (C12M) close behind at 33.1%. Peptide and protein chemistry (C07K) appears in 22.0% of records. Separation processes, optical monitoring and centrifuge apparatus each account for under 4%, marking them as comparatively thin areas of claim coverage.
Is the perfusion cell culture patent field growing or slowing down?
Filings rose to a peak of 24 records in 2018 and have not returned to that level in this dataset. Because publication typically lags filing by around 18 months, the most recent years — including the partial 2026 figure — understate real activity, and a clearer picture will only emerge once pending applications publish. No growth rate is stated here because fewer than four complete years remain once that lag is accounted for.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Perfusion Cell Culture Processes covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.